866-997-4948(US-Canada Toll Free)

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 44 Pages

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Acyl CoA Desaturase - Pipeline Review, H2 2017'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including -cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.

The report 'Acyl CoA Desaturase - Pipeline Review, H2 2017' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 4, 1 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Oncology, Dermatology and Infectious Disease which include indications Non-Alcoholic Steatohepatitis (NASH), Acne Vulgaris, Colorectal Cancer, HIV-Associated Lipodystrophy Syndrome, Liver Fibrosis, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Overview 6
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics Development 16
Daiichi Sankyo Co Ltd 16
Galmed Pharmaceuticals Ltd 16
Johnson & Johnson 16
Novartis AG 17
Takeda Pharmaceutical Co Ltd 17
Thesan Pharmaceuticals Inc 18
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles 19
Aramchol - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
T-3764518 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
TSN-2898 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Products 31
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products 32
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Product Development Milestones 33
Featured News & Press Releases 33
Nov 07, 2017: Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference 33
Oct 19, 2017: Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH) 33
Oct 05, 2017: Galmed Pharmaceuticals Announces Publication of Data on Aramchol Mechanism of Action in Hepatology Communications, Data Will Also Be Presented at AASLD 34
Apr 05, 2017: Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis 34
Jan 09, 2017: Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study 35
Sep 22, 2016: Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol Effects Juvenile Population 36
Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China 36
Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial 37
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 37
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 38
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 39
Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America 40
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 40
Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production 41
Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 15
Pipeline by Daiichi Sankyo Co Ltd, H2 2017 16
Pipeline by Galmed Pharmaceuticals Ltd, H2 2017 16
Pipeline by Johnson & Johnson, H2 2017 17
Pipeline by Novartis AG, H2 2017 17
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 18
Pipeline by Thesan Pharmaceuticals Inc, H2 2017 18
Dormant Projects, H2 2017 31
Discontinued Products, H2 2017 32

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Stage and Molecule Type, H2 2017 15

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *